Page 4 - Valency Communications News Today

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation...

Intratumoral injection of allogeneic pro-inflammatory dendritic cells ("ilixadencel") substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established in

Investegate announcements from Immunicum AB, Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus AB

Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirationsThe Company's stock to continue trading under ticker

Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirationsThe...

JANUARY - MARCH IN SUMMARY Net sales for the period amounted to KSEK 1,794 (-).Result for the period amounted to KSEK -27,582 (-41,571).Earnings and diluted earnings per share totaled SEK -0.14 (-0.25).Immunicum

Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced the appointment of Leopold Bertea

COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5'-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical

Immunicum AB , a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming... | April 19, 2022

Investegate announcements from Immunicum AB, Immunicum AB: Immunicum AB (publ) Publishes the Annual Report for 2021